Das Medizinportal


ASCO 2017 – Update Neuroendokrine Neoplasien (S. 18–22)
Christian Fottner und Matthias M. Weber, Mainz 

  1. Fottner C, Miederer M, Musholt TJ, Weber MM Neuroendokriner Neoplasien des Gastrointestinaltrakts – Diagnostik und interdisziplinäre Therapie. Best practice Onkologie 2013; 6(8): 6–14
  2. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009 Oct 1; 27(28): 4656–63
  3. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 Jul 17; 371(3): 224–33 
  4. Wolin EM et al. Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): the CLARINET extension study. J Clin Oncol 35, 2017 (suppl; abstr 4089)
  5. Phan T. et al. Effect of lanreotide depot (LAN) on 5-hydroxyindolacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropancreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study. J Clin Oncol 35, 2017 (suppl; abstr 4095)
  6. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017 Jan 12; 376(2): 125–135
  7. Mandair D. et al. Predictors of outcome in patients treated with peptide radio-labelled receptor target therapy (PRRT). J Clin Oncol 35, 2017 (suppl; abstr 4090)
  8. Sharma R. et al. 68Ga-DOTATATE PET/CT to predict response to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours (NETs). J Clin Oncol 35, 2017 (suppl; abstr 4093)
  9. Reidy DL et al. Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201. ). J Clin Oncol 35, 2017 (suppl; abstr 4094)
  10. Marcondes GF et al.  Lobectomy with mediastinal nodal dissection versus partial lobectomy in patients with bronchial carcinoid tumors: ANCDB analysis. ). J Clin Oncol 35, 2017 (suppl; abstr 8549)
  11. Marcondes GF et al.  Impact of adjuvant chemotherapy in non-metastatic node positive bronchial neuroendocrine tumors (BNET). J Clin Oncol 35, 2017 (suppl; abstr 8533)
  12. Kujtan LA et al. The role of adjuvant therapy in the management of resected large cell neuroendocrine carcinoma (LCNEC) of the lung: A National Cancer Database (NCDB) analysis. J Clin Oncol 35, 2017 (suppl; abstr 8529)
  13. Derks J. et al. Genetic subtypes of large cell neuroendocrine carcinoma (LCNEC) to predict response to chemotherapy. J Clin Oncol 35, 2017 (suppl; abstr 9061)
  14. Chae YK et al. Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP). J Clin Oncol 35, 2017 (suppl; abstr 8517)
  15. Kim HS et al. Association of PD-L1 expression with tumor infiltrating immune cells and mutation burden in the high grade neuroendocrine carcinoma of the lung.  J Clin Oncol 35, 2017 (suppl; abstr 8564)

Nebenwirkungsmanagement durch Komplementärmedizin (S. 33–37)
Petra Voiss, Essen

  1. Dobos GJ, Voiss P, Schwidde I, Choi KE, Paul A, Kirschbaum B, Saha FJ, Kuemmel S.  Integrative oncology for breast cancer patients: introduction of an expert-based model. BMC Cancer 2012 Nov 21; 12: 539. doi: 10.1186/1471-2407-12-539
  2. Horneber M et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integrative cancer therapies 2012; 11: 187–203
  3. Memorial Sloan Kettering Cancer Center. About Herbs. In:http://www.mskcc.org/cancer-care/integrative-medicine/about-herbs-botanicals-other-products: Memorial Sloan Kettering Cancer Center
  4. Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM et al. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw 2015; 13(8): 1012–39
  5. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2012; 11: CD006145
  6. Steindorf K, Schmidt ME, Klassen O et al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Annals of oncology/ESMO 2014; 25: 2237–2243
  7. Schmidt ME, Wiskemann J, Armbrust P et al. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int J Cancer 2015; 137: 471–480
  8. Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017 May 6; 67(3): 194–232. doi: 10.3322/caac.21397. Epub Apr 24
  9. Molassiotis et al. Acupuncture for Cancer-Related Fatigue in Patients With Breast Cancer: A pragmatic Randomized Controlled Trial. J Clin Oncol. 2012 Dec 20; 30(36): 4470–6
  10. Wu X et al. Effectiveness of acupuncture and related therapies for palliative care of cancer: overview of systematic reviews. Sci Rep 2015; 26: 16776
  11. Mao JJ, Farrar JT, Bruner D et al. Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial. Cancer 2014; 120: 3744–3751
  12. Zick SM, Sen A, Wyatt GK, Murphy SL, Arnedt JT, Harris RE. Investigation of 2 Types of Self-administered Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors: A Randomized Clinical Trial. JAMA Oncol 2016 Nov 1; 2(11): 1470–1476. doi: 10.1001/jamaoncol.2016.1867
  13. Johns SA, Brown LF, Beck-Coon K, Monahan PO, Tong Y, Kroenke K (2015) Randomized controlled pilot study of mindfulness-based stress reduction for persistently fatigued cancer survivors. Psychooncology.  Aug;24(8):885-93. doi: 10.1002/pon.3648. Epub 2014 Aug 17 
  14. Tröger W, Jezdić S, Zdrale Z, Tišma N, Hamre HJ, Matijašević M. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer 2009 Jul 6; 3: 35–45
  15. Sprod LK. Effects of yoga on cancer-related fatigue and global side-effect burden in older cancer survivors. Journal of Geriatric Oncology 2015; 6: 8–14
  16. Chandwani KD, Perkins G, Nagendra HR, Raghuram NV, Spelman A et al. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol 2014 Apr 1; 32(10): 1058–65
  17. Cramer H, Lange S, Klose P, Paul A, Dobos G. Can yoga improve fatigue in breast cancer patients? A systematic review. Acta Oncol 2012 Apr; 51(4): 559–60. doi: 10.3109/0284186X.2011.637960
  18. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev 2017 Jan 3; 1: CD010802. doi: 10.1002/14651858.CD010802.pub2
  19. Zeng Y et al. Health benefits of qigong or tai chi for cancer patients: a systematic review and meta-analyses. Complementary therapies in medicine 2014; 22: 173–186
  20. Eghbali M, Yekaninejad MS, Varaei S, Jalalinia SF, Samimi MA, Sa'atchi K. The effect of auricular acupressure on nausea and vomiting caused by chemotherapy among breast cancer patients. Complement Ther Clin Pract 2016 Aug; 24: 189–94. doi: 10.1016/j.ctcp.2016.06.006. Epub 2016 Jul 5
  21. Marx W et al. Ginger-Mechanism of Action in Chemotherapy-induced Nausea and Vomiting: A Review. Critical Reviews in Food Science and Nutrition 7:0. [Epub ahead of print]
  22. Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial. Support Care Cancer 2002 Apr; 10(3): 237–46. Epub 2001 Dec 18
  23. Redman MG et al. The efficacy and safety of probiotics in people with cancer: a systematic review. Annals of oncology/ESMO 2014; 25: 1919–1929
  24. Hershman DL, Unger JM, Crew KD et al. Randomized doubleblind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013; 31(20): 2627–2633
  25. Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B et al Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 2012 Aug 15; 12: 355
  26. Lu W, Giobbie-Hurder A, Freedman R et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial. San Antonio Breast Cancer Symposium 2016
  27. Awad D et al.  Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy. J Clin Oncol 2015; 33: 15_suppl
  28. Aghamohammadi A, Hosseinimehr SJ. Natural Products for Management of Oral Mucositis Induced by Radiotherapy and Chemotherapy. Integr Cancer Ther 2016 Mar; 15(1): 60–8. doi: 10.1177/1534735415596570
  29. Mutluay Yayla E, Izgu N, Ozdemir L, Aslan Erdem S, Kartal M. Sage tea-thyme-peppermint hydrosol oral rinse reduces chemotherapy-induced oral mucositis: A randomized controlled pilot study. Complement Ther Med 2016 Aug; 27:58–64. doi: 10.1016/j.ctim.2016.05.010. Epub May 25
  30. Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S et al. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol 2015 Aug 1; 33(22): 2444–9. doi: 10.1200/JCO.2014.60.4587
  31. Peppone LJ, Janelsins MC, Kamen C et al.  The effect of YOCAS(c)(R) yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy. Breast cancer research and treatment 2015; 150: 597–604
  32. Irwin M. et al.  Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: The hormones and physical exercise (HOPE) study, 36th Annual San Antonio Breast Cancer Symposium (SABCS) 2013: Abstract S3-03. Presented December
  33. Chien TJ, Liu CY, Chang YF et al. Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis. Journal of alternative and complementary medicine 2015 21: 251–260
  34. Uhlenbruck G,  Vanl R, Schneider B et al. Reduced side-effects of adjuvant hormone therapy in breast cancer patients by complementary medicine. In Vivo 2010; 24: 799–802
  35. Lesi G. Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT). Journal of Clinical Oncology 2016; 34: 1795–802
  36. Cramer H, Rabsilber S, Lauche R et al. Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial. Cancer 2015. doi: 10.1002/cncr.29330 Epub March 4
  37. Cramer H, Lauche R, Paul A, Langhorst J, Kümmel S, Dobos GJ. Hypnosis in breast cancer care: a systematic review of randomized controlled trials. Integr Cancer Ther 2015 Jan; 14(1): 5–15. doi: 10.1177/1534735414550035. Review

Die rezessive Variante des Lynch-Syndroms – der Wolf im Schafspelz: Biallelische (Constitutionelle) Mismatch-Repair Mutationen (BMMRD – CMMRD) (S. 46–50)
Gabriela Möslein, Wuppertal 

  1. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. Leitlinienprogramm Onkologie: S3-Leitlinie Kolorektales Karzinom, Langversion 1.1; 2014, Registrierungsnummer: 021–007OL
  2. Vasen HF A, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62(6): 812–23
  3. Ricciardone MD, Ozcelik T, Cevher B, et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 1999, 59: 290–293 
  4. Wang Q, Lasset C, Desseigne F, et al. Neurofibromatosis and early onset of cancers in hMLH1- deficient children. Cancer Res 1999, 59: 294–297
  5. Durno CA, Aronson M, et al. Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 2012, 59: 652–6
  6. Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 2014, 50(5): 987–96 
  7. De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004, 74: 954–964
  8. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 2008, 124: 105–122 
  9. Ingham D, Diggle CP, Berry I, Bristow CA, Hayward BE, Rahman N, et al. Simple detection of germline microsatellite instability for diagnosis of constitutional mismatch repair cancer syndrome. Hum Mutat 2013, 34(6): 847–52
  10. Rana HQ, Syngal S, Biallelic. Mismatch Repair deficiency: Management and Prevention of a devastating manifestion of the Lynch syndrome. Gastroenterology 2017, 152: 1254–57
  11. Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet 2015, 52(11): 770–8 
  12. Wimmer K, Kratz CP, Vasen HF a, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium “care for CMMRD” (C4CMMRD). J Med Genet 2014, 51(6): 355–65 
  13. Vasen HFA, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet 2014, 51(5): 283–93
  14. Devaud N, Gallinger S. Chemotherapy of MMR-deficient colorectal cancer. Fam Cancer  2013, 12: 301–6
  15. Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, et al. Recommendations on Surveillance and Management of Biallelic. 2017, 1605–14
  16. Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, et al. Syndrome Based on Microsatellite Instability and Lymphocyte. Gastroenterology 2015, 1017–29
  17. Win AK, Jenkins MA, Dowty JG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomark Prev 2016, 26: 404–412
  18. Yurgelun MB, Allen B, Kaldate RR, Judkins T, et al. Identificatation of a variety of mutations in cancer predisposition genes in patients whith suspected Lynch Syndrome. Gastroenterology 2015, 149(3), 604–613